— Solutions by Industry: Pharma & Biotech —
Make capital decisions as
evidence-based as your science.
Finario brings the same rigor to your Capex program that your organization brings to its pipeline.
Because the stakes of capital misallocation


can be measured in patients, not just returns.


In pharma and biotech, capital investment decisions carry consequences that go well beyond the balance sheet. Manufacturing capacity, GMP compliance, pipeline investment, and facility modernization all compete for an often constrained budget.
Pipeline-to-Manufacturing Alignment
Coordinating capital investment with clinical development timelines requires cross-functional visibility that other systems simply cannot provide. Finario connects capital planning to strategic outcomes, so facility investment decisions align with pipeline realities.
Facility Investment
Regulatory requirements generate significant non-discretionary Capex that must be planned, approved and tracked with audit-grade precision. Finario’s standardized workflows, timestamped approval chains, and SOC 2 Type 2 security provide the audit trail your organization demands.
Speed-to-Capacity Under Pressure
When a product reaches late-stage trials or achieves regulatory approval, the window to build capacity is narrow, and the cost of delay is enormous. Finario’s automated approval workflows compress authorization cycles so capital deploys at the speed the business requires.
Global Footprint
Large pharma companies manage capital programs spanning manufacturing sites, R&D facilities, and distribution networks across multiple countries. Finario provides a single, consolidated portfolio view across every site, with live ERP actuals and consistent project evaluation criteria.
Capital intensity at this scale
requires a system built for it.
The Art & Science of Capital Planning
Capital authorization is just the start. The real work begins the moment a project is approved: tracking spend, reforecasting against milestones, surfacing variance before it compounds, and more.
In pharma, where a single facility investment can run to hundreds of millions, that ongoing intelligence is essential.
Every Decision Documented
In a GxP environment, every capital decision is a potential audit point. Who approved it, on what basis, when, and with what information?
Finario’s timestamped, role-based approval chains and full audit history provide the governance documentation regulatory bodies require, without manual reconstruction after the fact.
Capital Culture as Competitive Advantage
Organizations that consistently outperform on ROIC share something beyond financial sophistication: They’ve made capital discipline a cultural practice, with standardized business cases, closed feedback loops, and a shared system of record every stakeholder can trust.
Finario makes that culture achievable, one capital cycle at a time.
Purpose-built for the precision
pharma & biotech capital programs demand.
From a $75K lab equipment request to a $400M biomanufacturing facility — every project in the same system, with the same rigor.
Standardized Business Case Templates
Leverage consistent evaluation criteria across sustainability, growth, automation, and sustaining projects, so that capital competes on merit across every plant and format.
Audit-Ready Approval Workflows
Requests are timestamped, including role-based approval chains with full history. Every capital decision is documented: who, what, when, and on what basis, making it ready for regulatory review without reconstruction.
Real-Time ERP Actuals Integration
Actuals from SAP, Oracle, JDE, Microsoft or other ERPs update automatically, so your forecast is always current, not last month’s batch run.
Scenario & Sensitivity Modeling
Model base, upside, and downside cases across raw material costs, construction timelines, and regulatory scenarios before committing capital.
Enterprise Capital Planning (ECP)
Finario picks up precisely where EPM leaves off, the moment capital is authorized. Track, reforecast, and optimize every project in a single connected system.
Post-Completion Reviews & Continuous Improvement
Close the gap between projected and actual returns. Build institutional memory of what works so your next capital cycle starts smarter than the last.
— UPCOMING WEBINAR —
Capex Recalibration Collection
Each 30-minute session is built to help you fix or fine-tune your most pressing Capex priorities. Get actionable insights on the capital planning practices that are driving results… and the habits that might be quietly holding your process back. Plus, see firsthand how enterprise Capex software turns best practices into action at every phase of the capital lifecycle; let our short public demo whet your appetite.
Finario presented a clear opportunity for us to change and modernize our culture when it came to managing Capex.
GROUP CFO, MEDICAL PRODUCTS COMPANY
Every project now has to earn its place. [We] track the share of capital spend that’s driving a return versus simply maintaining the business, using project categorization inside Finario to keep the portfolio weighted toward projects that pay off.
DIRECTOR, CAPITAL ENGINEERING, MEDICAL DEVICES Company
The ability to track actual costs against what’s been approved in Finario has been great.
GROUP CFO, MEDICAL PRODUCTS COMPANY